Premium for New Drug Development Should Be Increased: Mr Miyoshi of IMS Japan

November 10, 2011
Masatake Miyoshi, vice president at IMS Japan, discussed problems with the NHI drug price system based on his own analysis of the financial effects of the revisions of NHI prices and dispensing fees carried out in 2010. He called for...read more